Bal Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bal Pharma's Board, meeting on August 11, 2025, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. Standalone revenue from operations fell to ₹6,563.51 lakhs from ₹7,312.74 lakhs a year earlier, a year-on-year decline of about 10%, while consolidated revenue slipped to ₹6,587.09 lakhs from ₹7,435.87 lakhs. Standalone net profit came in at ₹32.31 lakhs (versus ₹35.86 lakhs in Q1 FY25) with EPS of ₹0.20, and consolidated net profit was ₹20.85 lakhs with EPS of ₹0.13. Statutory auditor SSJNB & Co. issued an unmodified (clean) limited-review opinion on both sets of results. The Board also approved the Employee Stock Option Plan-2025 subject to shareholder approval, scheduled the 38th AGM for September 25, 2025, and disclosed that ₹969.37 lakhs is recoverable from loss-making subsidiary Lifezen Healthcare and ₹155.22 lakhs from Balance Clinic LLP, both of which have negative net worth.
A weaker top line and thin profits point to short-term earnings pressure for shareholders, though the clean audit opinion and absence of exceptional items limit the downside surprise. Investors should track subsidiary recoverability and the upcoming ESOP-2025 and AGM decisions for further direction.